|Brooks Automation Acquires Life Sciences Consumables Provider 4titude, Ltd. and Secures $200 Million Term Loan|
Founded 12 years ago by industry veterans, 4titude is widely recognized for its innovative PCR plates which are used to "amplify" or copy small segments of DNA, a significant factor in accelerating research. The company also manufactures a range of sealing and sequencing tubes related to bench top instrumentation. 4titude supplies consumable PCR plates to more than 1200 global customers in the pharma, biotech, academic, and biobanking markets.
“4titude is a natural addition to Brooks Life Science offerings,” commented
Co-founders of 4titude,
Over the last two years, 4titude has delivered more than 20% annual growth and generated approximately
Brooks is a leading worldwide provider of automation and cryogenic solutions for multiple markets including semiconductor manufacturing and life sciences. Brooks’ technologies, engineering competencies and global service capabilities provide customers speed to market and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments. Since 1978, Brooks has been a leading partner to the global semiconductor manufacturing market. Since 2011, Brooks has applied its automation and cryogenics expertise to meet the sample storage needs of customers in the life sciences industry. Brooks’ life sciences offerings include a broad range of products and services for on-site infrastructure for sample management in temperatures of -20°C to -150°C, as well as comprehensive outsource service solutions across the complete life cycle of biological samples including collection, transportation, processing, storage, protection, retrieval and disposal. Brooks is headquartered in
“Safe Harbor Statement” under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Brooks' financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include, but are not limited to statements about the anticipated benefits of the acquisition of 4titude, the expected future capabilities of the combined companies, and the use of proceeds of the senior term loan. Factors that could cause results to differ from our expectations include the following: potential difficulties with the integration of the 4titude business into Brooks Life Science Systems and potential adverse reactions or changes to business relationships resulting from Brooks’ ownership of the 4titude business. In addition, actual results are subject to other risks that relate more broadly to Brooks’ overall business, including those that we have described in our filings with the